Developing a new treatment to improve muscle strength in older adults after hip fractures
Preclinical Development of a Novel Therapeutic to Rejuvenate Aging Muscle Stem Cells and Enhance Muscle Strength and Function Post Hip Fracture
This study is testing a new treatment that helps older adults, especially those who have had hip fractures, regain muscle strength and improve their recovery after surgery by boosting their muscle repair cells.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ridgeline Therapeutics, LLC NIH-funded |
| Lab location | 1 site (Houston, UNITED STATES) |
| Project ID | NIH-10696182 on NIH RePORTER |
What this research studies
This research focuses on addressing the decline in muscle mass and strength that occurs with aging, particularly in older adults who have suffered hip fractures. The approach involves developing a novel small molecule treatment that targets and rejuvenates aging muscle stem cells, which are crucial for muscle repair and regeneration. By reactivating these cells, the research aims to enhance muscle strength and functional recovery post-surgery, ultimately improving the quality of life for elderly patients. The study will evaluate the effectiveness of this treatment in restoring muscle function and reducing the risk of further injuries.
Who could benefit from this research
Good fit: Ideal candidates for this research are older adults aged 60 and above who have experienced a hip fracture and are facing challenges in muscle recovery.
Not a fit: Patients who are younger than 60 or those who have not suffered a hip fracture may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve recovery outcomes and quality of life for older adults recovering from hip fractures.
How similar studies have performed: While there have been attempts to improve muscle strength in the elderly, this specific approach using NNMT inhibitors is novel and has not been tested in this context before.
Where this research is happening
Houston, UNITED STATES
- Ridgeline Therapeutics, LLC — Houston, United States (Active)
Researchers
- Principal investigator: Neelakantan, Harshini — Ridgeline Therapeutics, LLC
- Study coordinator: Neelakantan, Harshini
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.